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DNAmethylation has been proposed to play a critical role in many cellular and
biological processes.
Objective
To examine the influence of Roux-en-Y gastric bypass (RYGB) surgery on genome-wide
promoter-specific DNAmethylation in obese patients. Promoters are involved in the initia-
tion and regulation of gene transcription.
Methods
Promoter-specific DNAmethylation in whole blood was measured in 11 obese patients (pre-
surgery BMI>35 kg/m2, 4 females), both before and 6 months after RYGB surgery, as well
as once only in a control group of 16 normal-weight men. In addition, body weight and fast-
ing plasma glucose were measured after an overnight fast.
Results
The mean genome-wide distance between promoter-specific DNA methylation of obese pa-
tients at six months after RYGB surgery and controls was shorter, as compared to that at
baseline (p<0.001). Moreover, postsurgically, the DNA methylation of 51 promoters was
significantly different from corresponding values that had been measured at baseline (28
upregulated and 23 downregulated, P<0.05 for all promoters, Bonferroni corrected).
Among these promoters, an enrichment for genes involved in metabolic processes was
found (n = 36, P<0.05). In addition, the mean DNA methylation of these 51 promoters was
more similar after surgery to that of controls, than it had been at baseline (P<0.0001). When
controlling for the RYGB surgery-induced drop in weight (-24% of respective baseline
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value) and fasting plasma glucose concentration (-16% of respective baseline value), the
DNA methylation of only one out of 51 promoters (~2%) remained significantly different be-
tween the pre-and postsurgery time points.
Conclusions
Epigenetic modifications are proposed to play an important role in the development of and
predisposition to metabolic diseases, including type II diabetes and obesity. Thus, our find-





An intervention that effectively reduces body weight in obese humans is Roux-en-Y gastric by-
pass (RYGB) surgery [1, 2]. This procedure reduces the functional volume of the stomach, and
thereby significantly shortens the gastric residence time of food. In addition to its pronounced
weight-reducing effects, RYGB surgery has been found to counteract many obesity-related meta-
bolic abnormalities [1], including an impaired glycemic metabolism [3] and type 2 diabetes [4].
Interestingly, variations of body weight and plasma glucose concentrations have previously
been associated with fluctuations in DNA methylation in humans, including promoter sites
[5]. Promoters are DNA regions upstream of a gene that is typically involved in the initiation
and regulation of gene transcription. DNA methylation represents an epigenetic mechanism
that regulates gene expression in human cells [6], and an aberrant DNA methylation profile
might contribute to many pathophysiological conditions observed in obese humans (e.g. [7],
[8]). Specifically, weight loss induced by both RYGB and a very low calorie diet (VLCD) has
been associated with promoter methylation changes in several genes.[9]
Against this background, the present study aimed to examine whether RYGB surgery has an
impact on DNAmethylation of gene promoters. To this study aim, genome-wide promoter-
specific DNA methylation in whole blood was measured twice in 11 obese patients, both before
and 6 month after RYGB surgery. In order to explore if RYGB surgery would reduce the
genome-wide distance between promoter-specific DNAmethylation of obese patients and
normal-weight humans, we also sampled whole blood from 16 normal-weight men.
Methods
Patients
Eleven obese patients who qualified for bariatric surgery according to international guidelines
[10] and were willing to undergo a RYGB procedure were included in the study. Patients were
recruited in to the study at their time of surgery between 20090820 and 20110210 and were fol-
lowed up 6 months after the surgery. Thus patient follow-up was performed February 2010 for
the first patient and August 2011 for the latest patient. Individuals included in the St Gallen co-
hort have been well characterized with regard to medical history, medical diagnoses and the in-
take of any prescribed medications. Subjects, who were included into our genome wide
studywere selected from the entire cohort based on two criteria. Individuals should have been
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only treated with therapeutics that pertained directly to the surgical intervention, e.g general
anesthesia. Furthermore, no medical diagnoses other than obesity were allowed to be abundant.
Written informed consent was obtained from all subjects, and the study was approved by the
ethic committee of Canton St. Gallen, Switzerland. Ethical approval for the study was obtained
20080717. A consort flowchart of the selection procedure is available as Fig. 1 along with the
Fig 1. Consort flowchart detailing how the subjects were rectuited and handled throughout the study.
doi:10.1371/journal.pone.0115186.g001
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Trend checklist (S1 Trend Checklist). The control group comprising 16 normal-weight men
was obtained from the control condition of an as of yet unpublished study (Clinical trial num-
ber: NCT01730742). This study was approved by the regional ethic committee in Uppsala
(regionala ekitprövningsnämnden i Uppsala, www.epn.se), Sweden and written, informed con-
sent was signed by all participants. At the time of recruitment, prospective registration of inter-
vention studies was not the norm and the authors opted to not register the study and ethical
approval from committee of Canton St. Gallen and the regional ethical committee at Uppsala
University was deemed sufficient. The authors confirm that all ongoing and related trials for
this intervention are now registered.
RYGB Procedures
During the RYGB procedure the largest part of the stomach was transected, and a small gastric
pouch of about 20–30 ml was then anastomized to the proximal jejunum with the diameter of
the pouch–jejunal anastomosis standardized to be about 12 mm. In addition, the biliopancrea-
tic limb is side to side anatomized to the jejunum 150 cm distal from the pouch–jejunal anasto-
mosis (Roux-en Y limb length, 150 cm).
Assessments
For the determination of promoter-specific DNAmethylation, whole blood was sampled after
an overnight fast in EDTA coated tubes, both at baseline (~1–2 weeks before the surgery) and
six months after RYGB. In the control group, whole blood was sampled in the morning after
nocturnal sleep (data are not shown). Until assay, all whole blood samples were kept frozen at
-80 C. Weight was measured while subjects were wearing light close. Fasting plasma glucose
(FPG) levels were measured by routine clinical laboratory analyses.
Methylation profiling
Genomic DNA was extracted using the phenol-chloroform method [11]. Bisulfite conversion
was performed with the EZ DNAMethylation—Gold kit (Zymo research. Cat. No. D5004).
The degree of DNAmethylation was determined by the Illumina 450K methylation chip (Illu-
mina, San Diego, USA). After the bisulfite converted DNA was hybridized to the array, fluores-
cence was measured using the Illumina iScan system. The raw data were processed using
GenomeStudio 2009–2. Blood samples from each subject were hybridized to the same physical
chip to minimize biases. Note that one subject of an initial sample of 12 obese humans was not
considered eligible for analysis because of technical failure during the methylation
profiling procedure.
Statistical analysis
Beta values were produced by Genomestudio (Illumina, San Diego, USA) and preprocessed
using Illumina Methylation Analyzer (IMA) package for R [12, 13]. Probes were excluded if
the detection p-value exceeded 5E-5 in 75% or more of the samples. Probes annotated to
known snp-sites or sex chromosomes were excluded prior to peak correction and quantile nor-
malization. An average on all CpG sites located in the same promoter region was calculated as
this analytical approach is proposed to be more meaningful from a biological perspective [14].
In total, 16724 promoter regions were used for subsequent analysis.
The initial analysis aimed to examine if RYGB surgery would reduce the genome-wide dis-
tance between promoter DNAmethylation of obese patients and the control group (compris-
ing normal-weight men). To this aim, the Euclidean distance of all promoters (i.e. 16724) was
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estimated for both presurgery time point vs. control group and postsurgery time point vs. control
group. These distances were then compared by means of a pairwise t test. In the second analy-
sis, presurgery DNA methylation of the above mentioned 16724 promoter regions was com-
pared with that obtained at six month after RYGB (controlled for multiple comparisons, i.e.
Bonferroni corrected). All significant promoter hits revealed by this pre/post comparison were




Descriptive statistics of the participants are shown in Table 1. As expected, following RYGB
surgery obese patients reduced their body weight by about 24%. However, patients’ weight re-
mained significantly higher compared to the normal-weight group. Fasting plasma glucose lev-
els were lower at six month after RYGB compared with baseline values (- 16%), with no
statistical difference between obese patients at the postsurgery time point and normal-
weight controls.
DNAmethylation
The mean genome-wide Euclidean distance between promoters of obese patients at six month
after RYGB surgery and controls was significantly shorter, as compared to that at baseline
(P<0.001, Fig. 2, left panel). An additional analysis demonstrated that at six month after
RYGB surgery, the DNAmethylation of 51 promoters was significantly different from corre-
sponding presurgery values (28 were upregulated and 23 were downregulated, P<0.05 for all
promoters, Bonferroni corrected; Table 2). The mean DNA methylation of these 51 promoters
was also more similar after surgery to that of controls, as compared to that at baseline
(P<0.0001; Fig. 2, right panel). Importantly, when controlling for the RYGB surgery-induced
drop in weight (-24% of respective baseline value) and fasting plasma glucose concentrations
(-16% of respective baseline value), the DNA methylation of only one out of 51 promoters
(~2%) remained significant at the postsurgery time point. An enrichment analysis of GO-
terms biological processes using DAVID functional analysis revealed an enrichment for genes
involved in metabolic processes (GO: 0008152) (P<0.05, Benjamini-Hochberg correction,
Fig. 3).







P-valueA vs. B P-ValueA vs. C P-ValueB vs. C
Mean ± SEM Mean ± SEM Mean ± SEM
Number of subjects 11 11 16 – – –
Females/Males (n/n) 7/4 7/4 0/16 – – –
Age, in years 47 ± 4 — 24 ± 1 – – –
Weight, in kg 132 ± 7 100 ± 6 78 ± 2 <0.001 <0.001 <0.01
Body mass index, kg/
m2
48.2 ± 2.2 36.4 ± 2.1 23.6 ± 0.6 <0.001 <0.001 <0.001
Morning FPG, mg/dl 6.0 ± 0.4 5.1 ± 0.2 5.4 ± 0.1 <0.05 0.08 0.09
Plasma insulin 14.12 (2.6)
P-values were calculated by means of t-tests. A one-tailed p-value < 0.05 was considered signiﬁcant. Abbreviations: FPG, fasting plasma glucose.
doi:10.1371/journal.pone.0115186.t001
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Discussion
Here we demonstrate that Roux-en Y gastric bypass (RYGB) surgery decreases the genome-
wide presurgery distance between promoter-specific DNAmethylation in whole blood of obese
patients and controls. These findings may form the basis for further investigations to unravel
the molecular effects of gastric bypass surgery, as epigenetic modifications are proposed to play
an important role in the development of metabolic diseases, including type 2 diabetes and obe-
sity [15].
We observed that the mean genome-wide distance between promoters of obese patients at
six month after RYGB surgery and controls was significantly shorter, than it had been before
surgery. Notwithstanding, when adjusting for the RYGB surgery-induced drop in body weight
and fasting plasma glucose, only one out of the 51 promoters that were significantly different
between presurgery and postsurgery time points (following Bonferroni correction) remained
significant. This suggests that the surgery-related influence on body weight and fasting plasma
glucose may play a causative role for concomitant changes in DNA methylation. Among the
promoter probes whose DNA methylation was significantly changed at 6 month after RYGB
surgery, several might account for some metabolic and clinical benefits that are typically ob-
served in response to the RYGB procedure. For instance, INCA1, whose methylation was
about 12% lower at 6 month after RYGB than it had been at baseline, may have an anti-cancer
effect due to its anti-proliferative properties [16]. Interestingly, cancer incidence and mortality
data from the Utah Cancer Registry have recently demonstrated that gastric bypass results in
lower cancer risk [17]. Another example of putatively clinically relevant changes in DNAmeth-
ylation is the ADK gene, whose methylation was about 10% lower at 6 month after RYGB than
it was at baseline. This gene encodes the enzyme adenosine kinase, which serves as a potential
regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides.
Fig 2. Mean (± SEM) genome-wide Euclidean distance between promoter-specific DNAmethylation of obese patients and controls before and at 6
month after Roux-en Y gastric bypass surgery. The left panel illustrates the mean Euclidean distance at genome-wide scale, whereas the right panel
shows the mean Euclidean distance at single-gene promoter scale. A two-tailed p-value<0.05 was considered significant.
doi:10.1371/journal.pone.0115186.g002
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Table 2. Whole-blood promoter-speciﬁc DNA methylation in obese patients before and at 6 month after Roux-en Y gastric bypass (RYGB)
surgery.
Gene % DNA Methylation level of the promoter region (Mean ± SEM) P-value
Baseline 6 months after RYGB surgery
SLC5A3;MRPS61 51.95±2.46 57.78±3.09 1.27E-02
MAN1B1;LOC100289341 3.99±0.54 8.67±0.94 7.10E-04
GGPS1;ARID4B 17.22±0.89 20.57±1.01 1.03E-03
CHP;EXD1 15.83±1.26 19.26±1.57 3.75E-02
LOH12CR1 17.46±1.09 19.17±0.81 1.44E-02
RNF19A 2.54±0.46 4.85±0.81 2.64E-02
SLC5A3;MRPS61 23.66±0.95 25.92±1.24 9.16E-05
C4orf33;SCLT1 23.66±0.34 25.83±0.35 4.26E-02
INVS;ERP44 47.3±0.52 48.97±0.48 4.86E-02
STRADA2 49.22±0.87 50.51±0.8 2.24E-02
STX16 3.79±0.26 5.2±0.2 1.60E-03
C9orf93 11.73±0.26 13.25±0.31 5.09E-03
NEDD8;GMPR2 13.37±0.58 14.48±0.21 4.50E-02
KCTD21;USP35 9.5±0.91 10.48±0.6 2.01E-02
SCLT1;C4orf33 15.18±0.2 16.45±0.22 1.97E-02
ABAT 1.94±0.21 2.6±0.18 2.85E-03
ERCC2 4.55±0.24 5.27±0.13 5.30E-04
TRIP11 1.26±0.14 2.04±0.25 2.18E-02
C19orf70;HSD11B1L 95.86±0.26 96.92±0.29 3.04E-02
STRADA2 22.87±0.26 23.61±0.21 9.43E-03
ZNF321 5.64±0.69 6.13±0.33 1.93E-02
CTR9 16.81±0.26 17.55±0.27 2.14E-03
DENND1C 16.29±0.45 16.78±0.3 3.98E-03
ZNF331 9.51±0.15 10.22±0.14 1.51E-02
PITRM1 10.54±0.4 10.92±0.25 8.90E-03
KPTN 4.83±0.28 5.41±0.21 4.47E-02
COX15;CUTC 2.2±0.13 2.84±0.26 2.23E-02
DDX10 3.89±0.21 4.43±0.28 4.27E-02
ZNF165 3.31±0.14 2.75±0.17 5.28E-03
PDF;COG8 8.63±0.47 8.05±0.43 2.93E-02
NUBP1 3.49±0.2 2.93±0.14 1.27E-02
GANAB;INTS5 2.58±0.16 2.07±0.11 4.78E-02
PMM2;TMEM186 3.47±0.14 2.7±0.09 2.87E-02
C4orf41;RWDD4A 4.88±0.27 4.22±0.22 1.66E-03
ADK 5.39±0.21 4.86±0.28 2.17E-03
CBX3;HNRNPA2B1 5.41±0.32 4.78±0.2 3.17E-02
C1D 9.63±0.55 8.82±0.46 3.38E-02
TMC6 6.79±0.72 5.8±0.57 1.49E-02
KIF22 7.75±0.27 6.97±0.36 4.38E-02
C16orf46 13.61±0.4 12.91±0.29 1.14E-02
CDK5RAP1 6.15±0.29 5.21±0.18 1.96E-02
RUNDC1;AARSD1 9.95±0.35 8.99±0.24 2.24E-02
STIP1 15.8±0.35 14.36±0.56 1.31E-02
MORC2 10.66±0.48 9.18±0.38 1.41E-02
INCA1 13.47±0.64 11.89±0.34 3.29E-05
(Continued)
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Interestingly, studies with non‐selective adenosine antagonists have shown that adenosine can
improve insulin secretion and lower glucose production [18, 19], as well as stimulate glucagon
secretion [20]. Thus, respective changes in DNAmethylation could very well contribute to the
improved in glucose metabolism and remission of diabetes after RYGB surgery [2, 4].
Adding further grist to the mill that RYGB surgery can cause epigenetic changes in obese
humans, a recent study has demonstrated that a RYGB-induced weight loss over six months
was correlated with widespread changes in promoter-specific DNA methylation in the skeletal
muscle of obese patients. Intriguingly, in this study it was also observed that a subset of genes
involved in insulin pathways showed an association between gene expression and promoter
methylation [21]. This supports the view that RYGB-induced differences in skeletal promoter-
specific DNA methylation are biologically relevant, and may thus contribute to the metabolic
health benefits that are often seen after RYGB surgery [1, 2, 4].
Several limitations apply to our study findings: They derive from whole blood samples. That
said, as long as they have not been validated in future studies, they cannot be extrapolated to
differences in DNAmethylation that may occur in other tissues in response to RYGB. Further-
more, the reader should take into account that our study is a six-month snapshot of RYGB-in-
duced changes in promoter-specific DNA methylation. This time point after surgery is
characterized by a pronounced catabolism and negative energy balance. Thus, caution is war-
ranted when extrapolating our DNA methylation findings to other time points after the sur-
gery, i.e. when the patients have stabilized their body weight. The control group in the present
study served as a reference for DNAmethylation levels under conditions of normal weight
and normal glucose metabolism. Thus, although our study findings indicate that the whole
blood DNAmethylation of promoters in obese patients goes towards methylation levels of
normal-weight subjects at six month after RYGB surgery, they do not allow firm conclusions
as to whether promoter-specific DNAmethylation per se has been reset to physiological
values. Finally, potential confound induced by factors not entered into our analysis cannot be
excluded (e.g. variation in DNA methylation induced by changes in environmental light
intensity).
In summary, our results show that RYGB surgery concurs with changes in methylation at
DNA sites that are typically involved in the initiation and regulation of gene transcripts. Bear-
ing in mind that we did not measure whole-blood gene transcription, an important next step is
Table 2. (Continued)
Gene % DNA Methylation level of the promoter region (Mean ± SEM) P-value
Baseline 6 months after RYGB surgery
TXNDC12;BTF3L4 14.83±0.69 13.5±0.61 8.79E-03
ST6GALNAC6 16.32±0.61 14.81±0.47 2.58E-02
NARS2 13.09±0.64 11.63±0.62 4.53E-04
ZNF324 5.52±0.37 3.9±0.16 1.93E-02
C10orf55;PLAU 23.93±0.65 22.2±0.35 4.62E-03
C1orf86;LOC100128003 41.12±1.55 38.84±1.53 1.82E-03
The table shows gene promoters whose DNA methylation differed between baseline and 6 months after RYGB surgery. Overall, a Bonferroni corrected
two-tailed p-value <0.05 was considered signiﬁcant.
1 The difference between the two entries is that they are from two different promoters. One is the promoter for two splice variants (topmost entry); the
other is cell type speciﬁc and only affects one splice variant of each gene.
2 There are two STRADA promoters associated with two sets of splice variants for that gene.
doi:10.1371/journal.pone.0115186.t002
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Fig 3. GO terms classification of genes (N = 51) whose promoter-specific DNAmethylation was significantly different between baseline (i.e before
Roux-en Y gastric bypass surgery) and at six month after surgery. An enrichment analysis of GO-terms biological processes using DAVID functional
analysis revealed an enrichment for genes involved in metabolic processes (GO: 0008152) (P<0.05).
doi:10.1371/journal.pone.0115186.g003
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to investigate if the RYGB-induced differences in promoter-specific DNAmethylation in
whole blood are associated with differences in gene expression.
Supporting Information
S1 Trend Checklist. The trend checklist lists where the relevant information about ethical
approvals and study outlines are found in the main paper.
(TIFF)
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